Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (51-60 of 204) with videos related to

Pageof 21
Sort By:
JTO Clinical and Research Reports|September 30, 2021
A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, <i>RET</i>-Rearranged NSCLCJustin F Gainor, Shirish Gadgeel, Sai-Hong I Ou, et al.
The Oncologist|March 21, 2019
Clinical Management of Adverse Events Associated with LorlatinibTodd M Bauer, Enriqueta Felip, Benjamin J Solomon, et al.
JAMA Oncology|January 1, 2016
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving RociletinibLecia V Sequist, Zofia Piotrowska, Matthew J Niederst, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2018
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLCIbiayi Dagogo-Jack, Sara E Stevens, Jessica J Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancerRyohei Katayama, Yuka Kobayashi, Luc Friboulet, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2019
Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional classDexter P Mendoza, Ibiayi Dagogo-Jack, Tianqi Chen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 22, 2017
A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain MetastasisIbiayi Dagogo-Jack, Michael Lanfranchi, Justin F Gainor, et al.
AJR. American Journal of Roentgenology|December 31, 2019
Imaging Features and Metastatic Patterns of Advanced <i>ALK</i>-Rearranged Non-Small Cell Lung CancerDexter P Mendoza, Jessica J Lin, Marguerite M Rooney, et al.
International Journal of Radiation Oncology, Biology, Physics|April 22, 2018
Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain MetastasesEmily Schapira, Harper Hubbeling, Beow Y Yeap, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2014
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinibJustin F Gainor, Carol A Sherman, Kathryn Willoughby, et al.
Pageof 21

Showing results (51-60 of 204) with videos related to

Sort By:
Pageof 21
JTO Clinical and Research Reports|September 30, 2021
A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, <i>RET</i>-Rearranged NSCLCJustin F Gainor, Shirish Gadgeel, Sai-Hong I Ou, et al.
The Oncologist|March 21, 2019
Clinical Management of Adverse Events Associated with LorlatinibTodd M Bauer, Enriqueta Felip, Benjamin J Solomon, et al.
JAMA Oncology|January 1, 2016
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving RociletinibLecia V Sequist, Zofia Piotrowska, Matthew J Niederst, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2018
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLCIbiayi Dagogo-Jack, Sara E Stevens, Jessica J Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancerRyohei Katayama, Yuka Kobayashi, Luc Friboulet, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2019
Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional classDexter P Mendoza, Ibiayi Dagogo-Jack, Tianqi Chen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 22, 2017
A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain MetastasisIbiayi Dagogo-Jack, Michael Lanfranchi, Justin F Gainor, et al.
AJR. American Journal of Roentgenology|December 31, 2019
Imaging Features and Metastatic Patterns of Advanced <i>ALK</i>-Rearranged Non-Small Cell Lung CancerDexter P Mendoza, Jessica J Lin, Marguerite M Rooney, et al.
International Journal of Radiation Oncology, Biology, Physics|April 22, 2018
Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain MetastasesEmily Schapira, Harper Hubbeling, Beow Y Yeap, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2014
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinibJustin F Gainor, Carol A Sherman, Kathryn Willoughby, et al.
Pageof 21